BridgeMD
Tests treatment safety and results for RSV Infection
Official title A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
ClinicalTrials.gov ID: NCT07482657
What this study is testing
What is zelicapavir?
zelicapavir is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for rsv infection.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Zelicapavir is a novel, orally administered, nonfusion replication inhibitor of RSV. It is being investigated in this Phase 2 study (EDP 938-203) as a potential treatment for RSV infection in both hospitalized and non-hospitalized children aged ≥28 days to ≤36 months who present with symptomatic RSV infection.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 28 to 36
You may be able to join if
- Participants diagnosed with RSV infection using an approved diagnostic assay, without known and/or documented coinfection with SARS-CoV-2 or influenza
- Participant has signs of RSV infection with onset ≤3 days (72 hours) at the time of randomization
- In the Investigator's opinion, the participant's caregiver understands and is able to comply with protocol requirements, instructions, and...
You likely can't join if
- Participant has any condition that in the opinion of the Investigator would interfere with the evaluation of the study drug or participant safety.
- Participant has underlying immune deficiency. Participants with immunoglobulin A deficiency are not excluded.
- Participant has had major surgery within 6 weeks prior to randomization or has major surgery planned during the course of the study.
- Participant is currently taking either chronically or has taken within 7 days prior to randomization, or is anticipated to receive during the course...
- Participant has received an investigational agent within the last 30 days or 5 half-lives of the investigational agent, whichever is longer.
The study team makes the final eligibility decision.
Where it's taking place
- Bangkok, Thailand
- Chiang Mai, Thailand
- Chiang Rai, Thailand
- Khon Kaen, Thailand
- Lampang, Thailand
- Lamphun, Thailand
- Maha Sarakham, Thailand
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 28 days to 36 months. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bangkok, Thailand; Chiang Mai, Thailand; Chiang Rai, Thailand; Khon Kaen, Thailand; Lampang, Thailand; Lamphun, Thailand and 1 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.